Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $317,400 - $537,000
30,000 Added 100.0%
60,000 $652,000
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $55,860 - $80,850
3,000 Added 11.11%
30,000 $562,000
Q4 2023

Feb 15, 2024

BUY
$17.1 - $22.26 $461,700 - $601,020
27,000 New
27,000 $585,000
Q1 2020

May 13, 2020

SELL
$26.15 - $77.24 $109,830 - $324,408
-4,200 Reduced 97.67%
100 $3,000
Q4 2019

Feb 10, 2020

BUY
$60.18 - $154.77 $180,540 - $464,310
3,000 Added 230.77%
4,300 $310,000
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $28,058 - $37,992
-200 Reduced 13.33%
1,300 $182,000
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $31,570 - $36,618
200 Added 15.38%
1,500 $275,000
Q1 2019

May 15, 2019

SELL
$89.33 - $163.65 $8.01 Million - $14.7 Million
-89,700 Reduced 98.57%
1,300 $207,000
Q4 2018

Feb 14, 2019

BUY
$81.94 - $139.71 $7.21 Million - $12.3 Million
88,000 Added 2933.33%
91,000 $8.72 Million
Q3 2018

Nov 14, 2018

BUY
$138.11 - $169.04 $82,866 - $101,424
600 Added 25.0%
3,000 $424,000
Q2 2018

Aug 14, 2018

SELL
$140.36 - $175.76 $28,072 - $35,152
-200 Reduced 7.69%
2,400 $376,000
Q1 2018

May 15, 2018

SELL
$152.15 - $192.33 $53 Million - $67 Million
-348,300 Reduced 99.26%
2,600 $419,000
Q4 2017

Feb 14, 2018

BUY
$60.72 - $167.34 $21.1 Million - $58.2 Million
347,800 Added 11219.35%
350,900 $57.8 Million
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $190,340 - $274,412
3,100
3,100 $193,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.